Surveillance of ischemic stroke recurrence after prescription of EFIENT tablets (prasugrel)-JMDC Cohort Study

Matsuoka Yomei0 个研究点目标入组 1,300 人开始时间: 2023年8月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have prescription of prasugrel or clopidogrel within the enrollment period (December 24, 2021 to May 31, 2027). The cohort entry date: first prescription date of prasugrel or clopidogrel within the enrollment period.
•2) Patients with acute ischemic stroke treated in hospital have diagnosis of atherothrombotic stroke or lacunar stroke during the past 30 days from the day before the cohort entry date.
•3) Patients who have risk factors for ischemic stroke recurrence.
•4) Patients who have medical records for the past 90 days from the day before the cohort entry date (Look back period).

•1) Patients who have prescription of prasugrel or clopidogrel in the look back period.
•2) No medical records from the day after the cohort entry date.
•3) Patients who have prescriptions of prasugrel and clopidogrel on the cohort entry date.

发起方

Matsuoka Yomei